fda ban on compounded semaglutide Manufacturing July 29, 2024: FDA issued

Zhou added, Small molecule GLP-1RAs, such as ECC5004, could potentially offer more dosing convenience and ease of use compared to existing GLP-1RA therapies. Under the agreement, AstraZeneca is granted exclusive global rights for the development and commercialization of ECC5004 for any indication in all territories except China, where Eccogene has the right to co-develop and co-commercialize in China alongside AstraZeneca

Under the stimulation of oxidative stress, keratinocytes are induced to produce CXC chemokine ligand (CXCL) 16, which further recruits CXCR6 + CD8 + T cells and the infiltration of such T cells in the skin is followed by the loss of melanocytes in vitiligo lesions (Li et al., 2017)

50 The exact mechanism through which GLP-1 was able to affect the production of cytokines in the CSMCs was beyond the scope of this study

B-10929)